A new field trial testing vaccines against highly pathogenic avian influenza (HPAI), commonly known as bird flu, has begun in England, offering a potential turning point in the UK’s ongoing battle against the disease. The trial, focused exclusively on turkeys – a species particularly vulnerable to HPAI – launched at the beginning of March and represents a significant step toward evaluating vaccination as a long-term disease control strategy. This turkey vaccine trial comes as the UK poultry sector faces substantial economic strain from repeated outbreaks.
The initiative follows recommendations from the UK joint industry and cross-government avian influenza vaccination taskforce, established to explore preventative vaccination of poultry. Currently, vaccination against bird flu is not permitted across the board in the UK, making this targeted exercise crucial for gathering real-world data. The trial will involve a limited number of birds kept under strict government oversight and vaccinated with approved UK and EU vaccines.
Why Turkeys Are Especially at Risk
Turkeys are uniquely susceptible to the severe effects of HPAI. Outbreaks in turkey populations often result in the rapid development of clinical signs and high mortality rates, leaving producers facing significant losses. According to estimates, the annual economic impact of avian influenza on the UK poultry industry can reach up to £174 million, affecting both government resources and farm businesses. The Department for Environment, Food & Rural Affairs highlights the increasing global concern surrounding HPAI, noting recent outbreaks have continued well into the summer months.
The British Poultry Council emphasized the importance of the trial, stating that it “marks an important milestone for our sector.” The council noted that HPAI has placed “enormous strain on producers” and that “sustainable, science-led solutions must be explored.” As reported by the British Poultry Council, the trial will help ensure future policy decisions are based on robust evidence and practical considerations.
A Collaborative Approach to Disease Control
The trial is being conducted under a collaborative framework involving both industry stakeholders and government agencies. This partnership reflects a broader recognition of the need for a coordinated response to the ongoing threat of avian influenza. The joint industry and cross-government taskforce underscores the commitment to finding effective ways to protect poultry flocks and safeguard the British poultry sector. Stringent biosecurity measures on farms remain the primary defense against infection, but vaccination is being investigated as a potential supplementary tool.
The results of the trial will provide valuable insights into how vaccination could operate within UK production systems, helping to inform future policy decisions. Researchers will be closely monitoring the birds for vaccine efficacy, potential side effects, and the overall impact on flock health. The data collected will be critical in determining whether vaccination can be integrated into a comprehensive disease control strategy.
The trial’s focus on turkeys is particularly significant given the species’ vulnerability. The British turkey sector has been disproportionately affected by recent outbreaks, making it a priority for research and intervention. The industry hopes that the trial will provide evidence to support the wider use of vaccination, offering a more sustainable solution to the challenges posed by HPAI.
The UK’s approach to avian influenza vaccination is being closely watched by other countries grappling with similar outbreaks. The results of this trial could have implications for global efforts to control the spread of the disease and protect poultry populations worldwide. The ongoing threat of HPAI underscores the importance of continued research, collaboration, and proactive measures to mitigate the risk.
England’s first turkey bird flu vaccine trial is underway, as Poultry World reports.
The next update on the trial’s progress is expected in late summer 2026, when preliminary data on vaccine efficacy and bird health will be released. Poultry farmers and industry stakeholders are encouraged to stay informed through official government channels and industry publications.
Have thoughts on this developing story? Share your comments below and join the conversation.
